These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 11404068

  • 21. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
    Rhomberg PR, Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2001; 40(1-2):45-9. PubMed ID: 11448563
    [Abstract] [Full Text] [Related]

  • 22. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R, Andrews JM.
    J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
    [Abstract] [Full Text] [Related]

  • 23. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN, Ballow CH, Schentag JJ, Johnson DM, Deinhart JA.
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [Abstract] [Full Text] [Related]

  • 24. Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli.
    Howard W, Biedenbach DJ, Jones RN.
    Clin Microbiol Infect; 2002 Jun; 8(6):340-4. PubMed ID: 12084101
    [Abstract] [Full Text] [Related]

  • 25. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development.
    Fix AM, Pfaller MA, Biedenbach DJ, Beach ML, Jones RN.
    Int J Antimicrob Agents; 2001 Aug; 18(2):141-5. PubMed ID: 11516937
    [Abstract] [Full Text] [Related]

  • 26. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
    Morrissey I, Robbins M, Viljoen L, Brown DF.
    J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
    [Abstract] [Full Text] [Related]

  • 27. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [Abstract] [Full Text] [Related]

  • 28. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
    Biedenbach DJ, Barrett MS, Croco MA, Jones RN.
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):45-50. PubMed ID: 9791757
    [Abstract] [Full Text] [Related]

  • 29. Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.
    Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2003 Sep; 47(1):373-6. PubMed ID: 12967753
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [In vitro activity of moxifloxacin against respiratory pathogens in Latin America].
    López H, Sader H, Amábile C, Pedreira W, Muñoz Bellido JL, García Rodríguez JA, Grupo MSP-LA.
    Rev Esp Quimioter; 2002 Dec; 15(4):325-34. PubMed ID: 12587037
    [Abstract] [Full Text] [Related]

  • 32. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA, Farrell DJ, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [Abstract] [Full Text] [Related]

  • 33. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
    Ballow CH, Jones RN, Johnson DM, Deinhart JA, Schentag JJ.
    Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
    [Abstract] [Full Text] [Related]

  • 34. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
    Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G, Jones RN.
    Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
    [Abstract] [Full Text] [Related]

  • 35. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
    Loza E, Morosini M, Negri MC, Almaraz F, Cantón R, Baquero F.
    Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
    [Abstract] [Full Text] [Related]

  • 36. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
    Pérez-Vázquez M, Román F, Aracil B, Cantón R, Campos J.
    J Clin Microbiol; 2004 Mar; 42(3):1185-91. PubMed ID: 15004073
    [Abstract] [Full Text] [Related]

  • 37. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
    Hedlin P, Blondeau JM.
    Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
    [Abstract] [Full Text] [Related]

  • 38. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E, Cantón R, Pascual A, Tubau F, Morosini MI, Almaraz F, Perea E, Martín R, Jones RN, Baquero F.
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [Abstract] [Full Text] [Related]

  • 39. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ.
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [Abstract] [Full Text] [Related]

  • 40. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
    Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA.
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):303-9. PubMed ID: 12151191
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.